Cold-fX

Last updated
Cold-FX
InventorAfexa Life Sciences Inc.
ManufacturerValeant Pharmaceuticals International
AvailableAvailable
Current supplierValeant Pharmaceuticals International
Website www.cold-fx.ca

Cold-FX is a product derived from the roots of North American ginseng ( Panax quinquefolius ). It was formulated by Jacqueline Shan [1] and originally manufactured by her company, Afexa Life Sciences (formerly called CV Technologies), [2] which was acquired by Valeant Pharmaceuticals in 2011.

Contents

There is little evidence to support that Cold-fx is effective in the common cold. [3] [4] All trials have been done by the manufacturer and there has been poor data reporting. [3] According to Health Canada's Natural Health Product Directorate records, the company claims that it may "help reduce the frequency, severity and duration of cold and flu symptoms by boosting the immune system". [5] COLD-FX is licensed by Health Canada as a Natural Health Product. [6] The efficacy of this extract has been tested in clinical trials conducted in collaboration with researchers from Canadian universities. COLD-FX has been assessed in 6 published randomized, double-blinded and placebo controlled clinical trials and 20+ published articles [7] [3] [8] [9] [10] [11]

Medical uses

There is no evidence that Cold-fx is effective in those infected with the common cold. [12] The effect of preventative use is not clear. [12] When used preventively it makes no difference on the rate of infections. [4] It also appears to have no effect on how bad the infections are. [4] There is tentative evidence that it may lessen the length of sickness when used preventively. [4] Blumenthal from American Botanical Council suggested that COLD-FX "represents a new class of herb-based therapeutic products" and is a "result of intensive scientific research on a natural herb". Clinical studies involving more than 1600 patients, showed that the active ingredient in COLD-FX can help reduce and prevent common cold and flu symptoms when taken daily., [8] [9] [10] [11] [13] [14]

Adverse effects

Individuals requiring anti-coagulant therapy such as warfarin should avoid use of American ginseng. Not recommended for individuals with impaired liver or renal function. It is not recommended in those who are pregnant or breastfeeding. Other adverse effects include: headaches, anxiety, trouble sleeping and an upset stomach. [12]

Criticism

The product has not been shown to reduce the number or severity of common colds. [4] There is tentative evidence that it may shorten colds in people who are otherwise healthy adults when taken preventively. [4] All studies posing "significant" results on its efficacy were funded by the manufacturer. [4]

Other criticisms point out that these studies have been small scale, with conspicuously shallow participant pools and lopsided gender distributions. [15] Researchers have pointed out that there aren't enough studies on the effects of any form of ginseng on the common cold to form any conclusions. [16]

Scientists have argued that the product has not been tested for its ability to treat a cold after an individual has been infected. [17] No studies have yet been performed to assess the possible long term side effects of taking the pills every day during the cold and flu season. [15] The manufacturer was criticized for making health claims about the product that have never been tested or scientifically verified. Until February 2007, the company advised a regimen of 18 pills over a course of 3 days in order to obtain "immediate relief" from a cold. Health Canada's review of the scientific literature confirmed that this is not a claim that it was entitled to make. [18] The company formulated a separate product for this usage. A CV Technologies press release explained the change in the dosing regimen as a choice to take a two-tier approach application to Health Canada. [19]

In 2015 a class action lawsuit was launched that claimed that the manufacturer misled people. [20] A B.C. Supreme Court judge refused to certify the class-action, but did not rule on the claim itself. [21] The appeal on this case has been dismissed. [22]

Related Research Articles

<span class="mw-page-title-main">Common cold</span> Common viral infection of the upper respiratory tract

The common cold or the cold is a viral infectious disease of the upper respiratory tract that primarily affects the respiratory mucosa of the nose, throat, sinuses, and larynx. Signs and symptoms may appear fewer than two days after exposure to the virus. These may include coughing, sore throat, runny nose, sneezing, headache, and fever. People usually recover in seven to ten days, but some symptoms may last up to three weeks. Occasionally, those with other health problems may develop pneumonia.

<span class="mw-page-title-main">Cold medicine</span> Medication taken to relieve cold symptoms

Cold medicines are a group of medications taken individually or in combination as a treatment for the symptoms of the common cold and similar conditions of the upper respiratory tract. The term encompasses a broad array of drugs, including analgesics, antihistamines and decongestants, among many others. It also includes drugs which are marketed as cough suppressants or antitussives, but their effectiveness in reducing cough symptoms is unclear or minimal.

<span class="mw-page-title-main">Ginseng</span> Root of a plant used in herbal preparations

Ginseng is the root of plants in the genus Panax, such as Korean ginseng (P. ginseng), South China ginseng (P. notoginseng), and American ginseng (P. quinquefolius), characterized by the presence of ginsenosides and gintonin. Ginseng is common in the cuisines and medicines of China and Korea.

<span class="mw-page-title-main">Influenza treatment</span> Therapy and pharmacy for the common infectious disease

Treatments for influenza include a range of medications and therapies that are used in response to disease influenza. Treatments may either directly target the influenza virus itself; or instead they may just offer relief to symptoms of the disease, while the body's own immune system works to recover from infection.

Dexatrim is an over-the-counter (OTC) dietary supplement meant to assist with weight loss. Dexatrim claims it "gives you the power to lose weight, curb binges, and keep you in control of your diet." Current Dexatrim products available are in capsule form and include Dexatrim Max Complex 7, Dexatrim Max Daytime Appetite Control, Dexatrim Natural Green Tea, and Dexatrim Natural Extra Energy. The major active ingredients found in current Dexatrim products include caffeine, green tea extract, Asian (Panax) ginseng root extract, and dehydroepiandrosterone (DHEA).

<span class="mw-page-title-main">Pleconaril</span> Antiviral drug

Pleconaril (Picovir) is an antiviral drug that was being developed by Schering-Plough for prevention of asthma exacerbations and common cold symptoms in patients exposed to picornavirus respiratory infections. Pleconaril, administered either orally or intranasally, is active against viruses in the Picornaviridae family, including Enterovirus and Rhinovirus. It has shown useful activity against the dangerous enterovirus D68.

Alternative treatments used for the common cold include numerous home remedies and alternative medicines. Scientific research regarding the efficacy of each treatment is generally nonexistent or inconclusive. Current best evidence indicates prevention, including hand washing and neatness, and management of symptoms.

<span class="mw-page-title-main">American ginseng</span> Species of flowering plant

American ginseng is a species of flowering plant in the ivy family Araliaceae. It is native to eastern North America and introduced in China. The specific epithet quinquefolius means "five-leaved", which refers to the typical number of leaflets per leaf. It is one of a group of taxa known as "ginseng".

<span class="mw-page-title-main">Ginseng tea</span> Herbal tea infusion

Ginseng tea, or insam-cha, is a traditional Korean tea made with ginseng. While it is called a tea, ginseng tea does not contain tea leaves. It is a herbal tea infusion made out of the ginseng plant's root. Ginseng is a perennial herb derived from the aromatic root of Panax Ginseng Meyer, also known as Korean ginseng. Ginseng grows in shady forests that are cool and damp. It is a slow-growing plant and is difficult to cultivate. It can take four to six years before the root is ready to be harvested. Ginseng roots have a forked and twisted appearance that somewhat resembles the human body.

<span class="mw-page-title-main">Brexpiprazole</span> Atypical antipsychotic

Brexpiprazole, sold under the brand name Rexulti among others, is a medication used for the treatment of major depressive disorder, schizophrenia, and agitation associated with dementia due to Alzheimer's disease. It is an atypical antipsychotic.

<span class="mw-page-title-main">Dupilumab</span> Drug used to treat allergic diseases

Dupilumab, sold under the brand name Dupixent, is a monoclonal antibody blocking interleukin 4 and interleukin 13, used for allergic diseases such as eczema, asthma and nasal polyps which result in chronic sinusitis. It is also used for the treatment of eosinophilic esophagitis and prurigo nodularis.

Risankizumab, sold under the brand name Skyrizi, is a humanized monoclonal antibody used for the treatment of plaque psoriasis, psoriatic arthritis, and Crohn's disease. It is designed to target interleukin 23A (IL-23A). It is given by subcutaneous injection.

<span class="mw-page-title-main">Upadacitinib</span> Chemical compound (medication)

Upadacitinib, sold under the brand name Rinvoq, is a medication used for the treatment of rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, and axial spondyloarthritis. Upadacitinib is a Janus kinase (JAK) inhibitor that works by blocking the action of enzymes called Janus kinases. These enzymes are involved in setting up processes that lead to inflammation, and blocking their effect brings inflammation in the joints under control.

<span class="mw-page-title-main">Baloxavir marboxil</span> Antiviral medication

Baloxavir marboxil, sold under the brand name Xofluza, is an antiviral medication for treatment of influenza A and influenza B. It was approved for medical use both in Japan and in the United States in 2018, and is taken as a single dose by mouth. It may reduce the duration of flu symptoms by about a day, but is prone to selection of resistant mutants that render it ineffectual.

Satralizumab, sold under the brand name Enspryng, is a humanized monoclonal antibody medication that is used for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease. The drug is being developed by Chugai Pharmaceutical, a subsidiary of Roche.

<span class="mw-page-title-main">Abrocitinib</span> Chemical compound

Abrocitinib, sold under the brand name Cibinqo, is a medication used for the treatment of atopic dermatitis (eczema). It is a Janus kinase inhibitor and it was developed by Pfizer. It is taken by mouth.

A respiratory syncytial virus vaccine, or RSV vaccine, is a vaccine that protects against respiratory syncytial virus. RSV affects an estimated 64 million people and causes 160,000 deaths worldwide each year.

Efgartigimod alfa, sold under the brand name Vyvgart, is a medication used to treat myasthenia gravis. Efgartigimod alfa is a neonatal Fc receptor blocker and is a new class of medication. It is an antibody fragment that binds to the neonatal Fc receptor (FcRn), preventing FcRn from recycling immunoglobulin G (IgG) back into the blood. The medication causes a reduction in overall levels of IgG, including the abnormal acetylcholine receptor (AChR) antibodies that are present in myasthenia gravis. It is also available coformulated with hyaluronidase.

Nirsevimab, sold under the brand name Beyfortus, is a human recombinant monoclonal antibody with activity against respiratory syncytial virus (RSV). It is a respiratory syncytial virus (RSV) F protein‑directed fusion inhibitor that is designed to bind to the fusion protein on the surface of the RSV virus.

References

  1. Keung, Nicholas (16 June 2014). "From Chinese village girl to Canadian CEO: Cold-FX founder writes her story". Toronto Star . Torstar . Retrieved 17 June 2014.
  2. "What is COLD-fX intended for?". Cold-fX: Frequently Asked Questions. Archived from the original on 2007-11-27. Retrieved 2007-11-24.
  3. 1 2 3 McElhaney J., et al. COLD-FX® Stimulates Cell Mediated Immune Response of Peripheral Leukocytes ex-vivo to Influenza Virus in National Hockey League Players. The Open Nutraceuticals Journal, 2010; 3: 25-29
  4. 1 2 3 4 5 6 7 Seida, JK; Durec, T; Kuhle, S (2011). "North American (Panax quinquefolius) and Asian Ginseng (Panax ginseng) Preparations for Prevention of the Common Cold in Healthy Adults: A Systematic Review". Evidence-Based Complementary and Alternative Medicine. 2011: 282151. doi:10.1093/ecam/nep068. PMC   3136130 . PMID   19592479.
  5. "Product Information". Archived from the original on 2013-10-23.
  6. Health Canada Natural Health Product Database.
  7. Predy GN, Goel V, Lovlin RE et al . Immune modulating effects of daily supplementation of COLD-FX (a proprietary extract of North American ginseng) in healthy adults. J Clin Biochem Nutr 2006;39:162-7
  8. 1 2 Vohra S, Johnston BC, Laycock KL et al. Safety and tolerability of North American ginseng extract in the treatment of pediatric upper respiratory tract infection: a phase II randomized, controlled trial of 2 dosing schedules. Pediatrics 2008; 122:e402-10.
  9. 1 2 Predy GN, Goel V, Lovlin R, Donner A, Stitt L, Basu TK. Efficacy of an extract of North American ginseng containing poly-furanosyl-pyranosyl-sacchardies for preventing upper respiratory tract infections: a randomized controlled trial. CMAJ. 2005;173:1043-1048.
  10. 1 2 McElhaney JE, Goel V, Toane B, Hooten J, Shan JJ. Efficacy of COLD-fX in the prevention of respiratory symptoms in community-dwelling adults: a randomized, double-blinded, placebo controlled trial. J Altern Complement Med. 2006;12:153-7.
  11. 1 2 McElhaney JE, Simor AE, McNeil S, Predy GN. Efficacy and safety of CVT-E002, a proprietary extract of panax quiquefolius in the prevention of respiratory infections in influenza-vaccinated community-dwelling adults: a multicenter, randomized, double-blind and placebo-controlled trial. Influenza Res Treat. 2011; 2011: 1-8.
  12. 1 2 3 Nahas, R; Balla, A (Jan 2011). "Complementary and alternative medicine for prevention and treatment of the common cold". Canadian Family Physician. 57 (1): 31–6. PMC   3024156 . PMID   21322286.
  13. Goel DP, Geiger JD, Shan JJ, Kriellaars D, Pierce GN. Doping-control urinalysis of a ginseng extract, Cold-FX®, in athletes. Int J Sport Nutr Exerc Metab. 2004;14:473-480. High KP, Case D, Hurd D, Powell B, Lesser G, Falsey AR, Siegel R, Metzner-Sadurski J, Krauss JC, Chinnasami B, Sanders G, Rousey S, Shaw EG. A randomized, controlled trial of panax quinquefolius extract (CVT-E002) to reduce respiratory infection in patients with chronic lymphocytic leukemia. J Support Oncol. 2012;10:195-201.
  14. McElhaney JE, Gravenstein S, Cole SK, Davidson E, O'neill D, Petitjean S, Rumble B, Shan JJ. A placebo-controlled trial of a proprietary extract of North American ginseng (CVT-E002) to prevent acute respiratory illness in institutionalized older adults. J Am Geriatr Soc. 2004;52:13-19.
  15. 1 2 "Fighting the Common Cold". ABC News. 2005-10-25.
  16. William Lin (2007-02-16). "Does ginseng really work? It depends on who you ask". The Ottawa Citizen. Archived from the original on 2008-06-21.
  17. "Ginseng Unproven in U.S." Los Angeles Times. 2008-02-18.
  18. Charlie Gillis (2007-03-26). "COLD-fX catches the sniffles again". Maclean's Magazine. Archived from the original on 2012-02-07.
  19. "COLD-fX Sets Record Straight: Health Canada's Approval of New Medical Claims Unchanged" (PDF). CV Technologies. March 5, 2007. Archived from the original (PDF) on October 2, 2011.
  20. "Cold-FX users were misled about top-selling cold and flu remedy, lawsuit alleges". National Post. March 31, 2015. Retrieved 23 June 2015.
  21. "Cold-FX class action lawsuit tossed - Toronto Star". thestar.com. 16 November 2016.
  22. "B.C. Appeal Court rejects class action lawsuit aimed at Cold-FX". financialpost.com May 2, 2018.